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Perioperative Risk Factor N %
CHF 51 44.7





Prior Pacemaker 18 15.8
Dyspnea 12 10.5
Postoperative Complication N %
New Pacemaker 10 8.7
Heart Block 8 7.0
Kidney Failure 8 7.0
New VSD Repair 5 4.4
Extra Ventilator 3 2.6
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Figure 2: Kaplan-Meier Curve of Septal Myectomy Patients
The gradual drops in the curve illustrate promising survival rate for patients. The data 
suggests that this is statistically significant, p < 0.001.
Classified
• Single-center retrospective review of all septal 
myectomy patients from 2006-2020 at LVHN
Reviewed
• Specific patient data gathered and assessed 
through in-house database
• Data was recorded in a unique REDCap 
database
Analyzed
• Descriptive statistics were used to analyze the 
significance of patient survival rates 
Objective
• This study seeks to evaluate the survival rates of patients 
with HCM that underwent the septal myectomy procedure.
Figure 1: Diagram of HCM and Septal Myectomy Procedure
Factor
Number of eventsa Number of censoredb
Sample sizeN % N %
HCM Patients 14 12.28 100 87.72 114
Table 1: Septal Myectomy Patient Mortality Summary
Events = Death Censored = Alive
Table 2: Pre-Septal Myectomy Risk Factors and Postoperative 
Complications
• Hypertrophic Cardiomyopathy (HCM) is a condition in 
which a portion of the heart becomes thickened without an 
obvious cause
• Hypertrophy = enlargement of tissue
• Drug-resistant patients  Septal Myectomy
• Surgical removal of enlarged portions of the heart
• Previous studies have found promising outcomes that 
include low mortality rates and rare occurrences of major 
complications
• Septal myectomy decreases symptoms of HCM
• 114 total patients 
• 14 died (12.28%) 
• Average survival time of 1134.14 days (3.10 years)
• 3 patients died within 30 days of the procedure (2.63%)
• 2 died due to excessive bleeding
• Major complications were not prevalent in the population
• Data is statistically significant, p < 0.001
• Survival rates are promising  only 12.28% died in a patient cohort 
that spans over 14 years
• Patients with several comorbidities are at higher 
risk for the septal myectomy procedure
• However, the overall survival rates are 
promising 
• Long-term survival rates of HCM patients that 
underwent septal myectomy illustrate success for 
this procedure
• Future research is encouraged to evaluate long-
term outcomes of septal myectomy over 20 years 
and understand the effects of pre-TAVR risk factors
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